about
sameAs
Mutations in the gene that encodes the F-actin binding protein anillin cause FSGSUrokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-betaAngiotensin II induced inflammation in the kidney and in the heart of double transgenic rats"Zebrafishing" for novel genes relevant to the glomerular filtration barrierMultiparametric Functional MRI: Non-Invasive Imaging of Inflammation and Edema Formation after Kidney Transplantation in MiceWegener's granulomatosisDiminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic miceEfficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertensionClinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome.A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing.Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitisImpact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.Tubular chimerism occurs regularly in renal allografts and is not correlated to outcome.Chimerism of metanephric adenoma but not of carcinoma in kidney transplants.Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts.Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy.Removal of elevated circulating angiopoietin-2 by plasma exchange--a pilot study in critically ill patients with thrombotic microangiopathy and anti-glomerular basement membrane disease.Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.Recent outbreak of hemolytic uremic syndrome in Germany.Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control studyNeurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adults.Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome.Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study.Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS).Ultrasound findings in EHEC-associated hemolytic-uremic syndrome and their clinical relevance.Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated by Escherichia coli O104:H4Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.Stat1 nuclear translocation by nucleolin upon monocyte differentiation.Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis.C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study.Cofilin-1 inactivation leads to proteinuria--studies in zebrafish, mice and humans.Angiopoietin-2 is a potential mediator of endothelial barrier dysfunction following cardiopulmonary bypass.Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C.Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial.Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.Prometheus--a new extracorporeal system for the treatment of liver failure.
P50
Q24293205-023FBE1B-5151-441F-BBE8-9B703AAE46A2Q24529131-FCD70422-68B7-4286-A4C5-B622498B90D7Q24800784-78C11FA6-ABC8-4697-B780-5C8D8C767D3DQ27010230-7DD3E21F-0E9A-4CD9-9713-22C1FC99A5FEQ27322569-1F0E7632-2B62-4E97-8217-BFF2EDDE08F3Q28236019-7C6B8AFB-4EB6-4C04-B64C-F12F6ED2E4C6Q28274074-77038792-654F-4B41-8B73-4EB05A14FE48Q28285275-81B7393F-CD8F-4571-A6B9-3BFA72DE3678Q30248744-FE741402-C059-4B55-A899-BF9430B4FF24Q30353115-4FD420D3-FA7F-4B44-9B41-AF9A9E5AB25AQ30433778-EBBCB32A-F4E8-4060-91D3-932427D27A6FQ30434677-633811EA-1A2D-45E2-82EE-CF22EF0F6233Q30453768-F42470F7-9D2C-4749-84D1-B5F210F422BCQ33199896-62130B6C-0D8D-4FCA-A632-05FDCA1B6F76Q33209554-CC72C21F-BD53-4783-9376-8612AC8CE0BCQ33214939-3B910D41-973D-4687-A5D2-E2C7A06ABCF5Q33372733-630D0637-688F-4A21-9FE0-D82D5DE225E5Q33391698-C3B591FE-F900-4838-8AEB-AC0E0543B766Q33394082-AD8EFC98-9108-40E6-B8D9-D68296976EE1Q33397631-957F8CAB-2B82-4D8E-AC34-5CE387A19F90Q33399130-10E4ED93-3D6D-42E3-BBEE-47B5F1A5A159Q33402456-571F2E47-1346-432D-9290-E23D0A332298Q33403418-7E8879D4-665F-4B22-B653-00EE41881B93Q33403833-F10BCA42-379B-4221-AC16-FF2E8F9A2AC3Q33405183-B0751F60-FF4A-4D11-994E-1F005A92AFECQ33411204-3CD59CFD-0997-4E80-AA47-2E3F814BF13FQ33429127-CD84F402-C950-4194-9377-FE3B9032ED0BQ33429876-888A3606-BB3E-487C-936C-3D8AD210824CQ33437468-D7C673A9-A2D0-4295-B644-AE57A9C18360Q33518524-891B30C5-304C-4C23-91B0-410E38C75B25Q33564333-DB020E91-C629-4C60-8F3D-C515C9B0DE26Q33620560-1D8F80FB-FCA4-4591-BD61-B47FF8D6888EQ33632242-5924C030-BA83-4804-AA1D-B8F99D94348AQ33691530-F58C4EB8-4EB7-48FA-AB88-F65F083A49BDQ34024826-F2AF4BB4-A043-4C82-9EA4-093D69E11EC5Q34044803-52017083-5213-4DE9-B425-F42F07ADA7B2Q34128558-B6340ADC-43E7-4987-B720-528A94BE9090Q34197044-D19BF921-99D6-4006-BA7C-67DA5918D845Q34254971-6619616A-3B1B-4F0E-AEE6-0E97CBF62706Q34279446-8A84007C-A89F-462F-95C4-8AEBE4F77CD2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hermann Haller
@ast
Hermann Haller
@en
Hermann Haller
@es
Hermann Haller
@nl
type
label
Hermann Haller
@ast
Hermann Haller
@en
Hermann Haller
@es
Hermann Haller
@nl
prefLabel
Hermann Haller
@ast
Hermann Haller
@en
Hermann Haller
@es
Hermann Haller
@nl
P106
P31
P496
0000-0002-8361-6446